乳腺癌患者新辅助化疗疗效因素的相关性研究

摘要

目的 新辅助化疗是乳腺癌治疗的重要手段之一.文中讨论乳腺癌术前穿刺活检雌激素受体(estrogen receptor,ER)、孕激素受体(progesterone receptor,PR)、人表皮生长因子受体(human epidermal growth factor receptor-2,HER-2)表达与新辅助化疗有效率的相关性.方法 采用免疫组化的方法检测40例接受新辅助化疗的乳腺癌患者ER、PR、HER-2表达情况,并观察化疗效果.结果 40例乳腺癌患者中,ER、PR阴性表达率分别为42.5%和52.5%,HER-2过表达率37.5%.ER阳性组与ER阴性组化疗有效率差异有统计学意义(P<0.05),PR阳性组与PR阴性组化疗有效率差异有统计学意义(P<0.05),而HER-2过度表达组与非过度表达组化疗有效率差异无统计学意义(P>0.05).结论 ER阴性、PR阴性的乳腺癌患者可能对化疗更敏感,有可能是新辅助化疗敏感性的预测指标.%Objective Neoadjuvant chemotherapy is one of the important means for the management of breast cancer. This stuffy was to investigate the correlation of the effectiveness of neoadjuvant chemotherapy with the expressions of ER, PR and HER-2 in the treatment of breast cancer. Methods We detected the expressions of ER, PR and HER-2 in 40 breast cancer patients receiving neoadjuvant chemotherapy by immunohistochemical methods and observed the therapeutic results. Results Among the 40 patients, the negative expressions of ER and PR were 42. 5 and 52. 5% , respectively, and the overexpression of HER-2 was 37. 5% . Statistically significant differences were found in chemotherapeutic effectiveness between the ER positive and ER negative groups ( P < 0. 05 ) as well as between the PR positive and PR negative groups ( P < 0. 05 ), but not between the HER-2 overexpressed and HER-2 non-over-expressed groups ( P > 0. 05 ). Conclusion ER and PR negative patients with breast cancer are more sensitive to chemotherapy. ER and PR negative may be the predictive factors of the sensitivity of neaodjuvant chemotherapy.